截至本公告披露日，公司已将上述暂时补充流动资金的 1 亿元闲置募集资金 全部归还至募集资金专用账户，并将上述募集资金的归还情况通知了保荐机构和 保荐代表人。 关于归还暂时用于补充流动资金的闲置募集资金 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生物制药股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日召开 第二届董事会第十七次会议和第二届监事会第十五次会议，审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的议案》，同意公司在确保不影响募集资 金投资项目实施及募集资金使用的情况下，使用不超过人民币 1 亿元闲置募集资 金暂时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月，并且 公司将随时根据募投项目的进展及需求情况及时归还至募集资金专用账户。具体 内容详见公司于 2024 年 8 月 23 日在上海证券交易所网站（www.sse.com.cn）和 指定媒体刊登的《百奥泰生物制药股份有限公司关于使用部分闲置募集资金暂时 补充流动资金的公告》（公告编号：2024-044 ...

Core Insights - The company reported significant growth in its H1 2025 financial results, with a revenue of 338 million and a net profit of 89 million, reflecting year-on-year increases of 69.69% and 308.29% respectively [1] - The growth in revenue and profit is primarily driven by the high demand in the peptide industry, particularly in the raw material and CDMO (Contract Development and Manufacturing Organization) sectors [2][3] Financial Performance - H1 2025 revenue reached 338 million, a 69.69% increase year-on-year - Net profit attributable to shareholders was 89 million, up 308.29% year-on-year - Operating cash flow net amount was 82 million, reflecting a 213.22% increase year-on-year - Q2 2025 revenue was 153 million, a 61.50% increase year-on-year, with net profit of 42 million, up 687.09% year-on-year [1] Business Segments - **Raw Material Business**: - Revenue for H1 2025 was 189 million, a 232.38% increase year-on-year, driven by increased exports of Semaglutide and Tirzepatide - The company has developed 21 self-researched peptide raw materials and has obtained production approvals for 14 varieties in the domestic market and 11 DMF registrations in the U.S. [2] - **CDMO Business**: - H1 2025 revenue was 42 million, a 72.93% increase year-on-year, supported by the clinical advancement of the RAY12225 injection project - The company has provided CDMO services for over 40 peptide innovation drug projects, with several drugs entering commercialization and clinical trial phases [3] Capacity Expansion - The company has successfully launched a new production line for peptide raw materials and has made progress on several other projects, enhancing its production capabilities - The company is positioned to benefit from the high demand in the peptide industry due to its comprehensive R&D pipeline and full-chain production services [4] Profit Forecast - Projected revenues for 2025-2027 are 751 million, 990 million, and 1.21 billion respectively, with net profits of 191 million, 273 million, and 349 million - The expected diluted EPS for the same period is 1.21, 1.73, and 2.22, with corresponding PE ratios of 33.21, 23.25, and 18.17 [5]

Group 1 - Company BAT1308 injection combined with BAT4706 injection and BAT8008 injection has received clinical trial approval for the treatment of advanced solid tumors [1] - BAT1308 is a humanized anti-PD-1 monoclonal antibody with high affinity for human PD-1, while BAT4706 targets CTLA-4 and is an IgG1 fully human monoclonal antibody [1] - BAT8008 is an antibody-drug conjugate targeting Trop2, demonstrating high anti-tumor activity and stability in plasma with a low shedding rate [1] Group 2 - BAT5906 has received approval for multiple clinical trials, including indications for w-AMD, DME, CRVO-ME, and pmCNV [2] - The company has completed Phase I, II, and III clinical studies for w-AMD, and the majority of patient recruitment for Phase III studies for DME has been completed [2] - The company is expected to achieve revenues of 889 million, 1.131 billion, and 1.699 billion yuan from 2025 to 2027, with a projected net profit of -459 million, -379 million, and 5 million yuan [2]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is recognized as a leading innovative drug enterprise, with projected revenues of 889 million RMB, 1,131 million RMB, and 1,699 million RMB for the years 2025, 2026, and 2027 respectively. The net profit attributable to the parent company is expected to be -459 million RMB, -379 million RMB, and 5 million RMB for the same years [7][8] Financial Performance Summary - Revenue for 2023 is reported at 705 million RMB, with a growth rate of 54.9%. The revenue is expected to grow at rates of 5.4%, 19.6%, 27.2%, and 50.2% for the years 2024 to 2027 respectively [6][8] - The net profit for 2023 is -395 million RMB, with projections of -510 million RMB for 2024, -459 million RMB for 2025, -379 million RMB for 2026, and a turnaround to 5 million RMB in 2027 [6][8] - Earnings per share (EPS) is forecasted to be -0.95 RMB for 2023, -1.23 RMB for 2024, -1.11 RMB for 2025, -0.91 RMB for 2026, and a positive 0.01 RMB for 2027 [6][8] Recent Developments - The company has received clinical trial approval for BAT1308, BAT4706, and BAT8008 for the treatment of advanced solid tumors. BAT1308 is a humanized anti-PD-1 monoclonal antibody, while BAT4706 targets CTLA-4, and BAT8008 is an antibody-drug conjugate targeting Trop2 [7] - BAT5906 has received approval for new indications, including retinal central vein occlusion and pathological myopia, with multiple clinical trials already underway [7]

Group 1 - The company Baiotai (688177.SH) has submitted its application for the national medical insurance negotiation for its drug Betanin (Citrulline Beta-Alanine Injection) [1] - The company is actively preparing for the related work regarding the medical insurance negotiation [1]

百奥泰（688177.SH）8月14日在投资者互动平台表示，公司枸橼酸倍维巴肽注射液（贝塔宁®）已申报 今年的国家医保谈判，正在积极筹备相关工作。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贝塔宁医保谈判进展如何？预计何时能进医保目录？ ...

Group 1: Company Updates - Huaguang Huaneng's production and operational activities are normal, with no significant changes in fundamentals [1] - Chuangyuan Co.'s new co-branded products are expected to have limited short-term impact on revenue and profit [1] - Shanghai Port's stock price has seen significant short-term increases, indicating potential irrational speculation [1] - *ST Gaohong's stock may face forced delisting due to major legal violations [1] - Jihua Group is under investigation by the CSRC for suspected information disclosure violations [1] - Hongtian Co.'s indirectly controlled subsidiaries have not yet generated revenue or profit from mask plates and glass substrate equipment orders [1] - Jishi Media does not engage in "State-owned Cloud" related businesses and is not involved in investments in currently released films [1] Group 2: Performance Metrics - Tongchen Beijian reported a net profit of 737 million yuan for the first half of the year, a year-on-year decrease of 17.34% [4] - Huanxun Electronics' consolidated revenue for July was 4.911 billion yuan, down 8.81% year-on-year [4] - Baiyun Airport's passenger throughput in July increased by 6.32% year-on-year [4] - Poly Development achieved a signed amount of 18.014 billion yuan in July, a year-on-year decrease of 28.85% [4] - Xiaoming Co. reported chicken product sales revenue of 75.14 million yuan in July, a month-on-month decrease of 22.35% [4] - Zhengbang Technology's pig sales revenue in July was 741 million yuan, up 91.38% year-on-year [4] - Yisheng Co. reported white feather chicken seedling sales revenue of 101 million yuan in July, a month-on-month decrease of 22.32% [4] - Tianbang Food's commodity pig sales revenue in July was 686 million yuan, a month-on-month increase of 1.59% [4] - Chongqing Construction's new contract amount in the second quarter was 8.101 billion yuan, a year-on-year decrease of approximately 42.97% [4] - Shunyu Optical Technology's mobile lens shipments in July decreased by 14.6% year-on-year [4] - Jianghuai Automobile's total sales in July were 25,197 vehicles, a year-on-year decrease of 21.73% [4] - Dual One Technology reported a net profit of 99.87 million yuan for the first half of the year, a year-on-year increase of 324.5% [4] - Wukuang Capital's performance report indicated a net profit of 525 million yuan for the first half of the year, a year-on-year decrease of 41.47% [4] - Greentown China expects a 90% year-on-year decrease in profit attributable to shareholders for the mid-2025 period [4] - Maoyan Entertainment anticipates a year-on-year decrease of approximately 29.8% to 43.8% in profit attributable to owners for the first half of the year [4] Group 3: Shareholding Changes - Ping An Life and Ping An Asset Management plan to reduce their holdings in China Happiness by no more than 3% [4] - Shiyun Circuit's new international intends to reduce its holdings in the company by no more than 3% [4] - Chuanwang Media's shareholders plan to reduce their holdings by no more than 1% [4] - Jian Ke Intelligent's actual controller plans to reduce their holdings by no more than 1.07% [4] - Hengong Precision's shareholders plan to reduce their holdings by no more than 3% [5]

证券代码： 688177 证券简称：百奥泰 公告编号：2025-048 百奥泰生物制药股份有限公司 自愿披露关于 BAT1308 注射液联合 BAT4706 注射液 及注射用 BAT8008 治疗晚期实体瘤获得药物临床试 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通 知书》，公司在研药品 BAT1308 注射液联合 BAT4706 注射液及注射用 BAT8008 治疗晚期实体瘤的临床试验申请获得批准。 根据《Clinical Development Success Rates2011-2020》公布的数据，通常情况 下对于抗肿瘤药物，一般 I/II 期临床研究阶段持续约 2 年时间，I 期完成进入 II 期的比率约 48.8%，II 期完成进入 III 期的比率约 24.6%，考虑到临床研究周期长、 投入大，过程中不可预测因素较多，临床试验、 ...

Core Viewpoint - The company Baiyao Tai (688177) has received approval from the National Medical Products Administration for its clinical trial application of BAT1308 injection combined with BAT4706 injection and BAT8008 injection for the treatment of advanced solid tumors [1] Group 1 - The clinical trial approval is a significant milestone for the company's research and development efforts in oncology [1] - The approved drugs are aimed at treating advanced solid tumors, indicating the company's focus on addressing critical medical needs in cancer treatment [1] - The announcement reflects the company's ongoing commitment to advancing its pipeline of innovative therapies [1]

Group 1 - The core point of the article is that Baiotai (688177.SH) has received approval from the National Medical Products Administration for its clinical trial application of BAT1308 injection combined with BAT4706 injection and BAT8008 injection for the treatment of advanced solid tumors [1] Group 2 - The approved clinical trial signifies a significant step forward for the company's research and development efforts in oncology [1] - The combination of these investigational drugs aims to address unmet medical needs in the treatment of advanced solid tumors [1] - This approval may enhance the company's position in the competitive biopharmaceutical market [1]